Rentschler Biopharma’s Post

We’re looking forward to the 25th Annual Simcyp Consortium Meeting, from September 24–26, 2024, at the Radisson RED Hotel, London Heathrow, UK. This event is a unique gathering of representatives from over 30 leading biopharmaceutical companies to discuss advancements in Physiologically Based Pharmacokinetic (PBPK) initiatives and their regulatory impacts. The Simcyp Consortium, with its blend of industry-leading members and innovative research, has significantly shaped drug development and regulatory practices worldwide. The meeting provides a platform for members to collaborate with Simcyp scientists, guiding the evolution of the Simcyp Simulator—a tool utilized by prominent regulators globally. To learn more about this event and the Consortium, please visit: https://lnkd.in/dTUcAmUC Here’s to celebrating 25 years of innovation, collaboration, and progress in drug development with the Simcyp Consortium! 🎉 #SimcypConsortium #DrugDevelopment #PBPKModeling

Let our AI integration help determine what intervention strategy is the most effective for your patient population and demonstrate the value of applying that strategy, both for health outcomes AND cost savings ...

Dive into our latest roundtable on the BIOSECURE Act's sweeping impacts on the biopharmaceutical world. How will it reshape innovation, safety, and the industry's path forward? Get insights straight from top industry experts!

We are proud to announce that MSD Polska has once again been awarded the prestigious status of a research and development center by the Minister of Development and Technology. This award confirms our continued commitment to: 💊 Developing innovative therapies 🔬 Conducting clinical trials in Poland 🇵🇱 Supporting Polish science and economy Key facts: - MSD Polska is one of 61 companies in the country with this status - We are among only 4 global biopharmaceutical companies with this distinction - We are currently conducting about 150 clinical trials involving about 3,700 Polish patients We are happy to support Polish science, economy and health care system. Together we are creating a healthier future! 💪 To read more: https://lnkd.in/eF2G2wh5 #MSDPolska #InnovationInHealthcare #researchanddevelopment #ClinicalTrials 🚀

If you haven’t signed up yet, there’s still chance… learn how you can strengthen an asset’s value proposition for investors, pharma/deal makers and payers. #marketaccess #BioTech #investors #dealmaking

🌟 Looking Ahead: December Events with Topscience Biotech! 🌟 As December unfolds, Topscience Biotech remain committed to supporting the global pharmaceutical industry. We look forward to connecting with industry partners, exchanging insights, and driving innovation together. 🚀 Let’s collaborate to shape the future of the industry. Stay tuned for updates, and we can’t wait to meet you there! 📅 Here’s What’s Coming Up in December: #TopscienceBiotech #PharmaceuticalInnovation #DecemberEvents #GlobalPartnership

How do #biopharma CEOs and R&D leaders pivot from strategy to action in modernizing the innovation engine? Together with senior executives from Bayer | Pharmaceuticals, Roche, Boehringer Ingelheim and Verband Forschender Arzneimittelhersteller e.V. (VFA), we present a collection of essays about reinventing pharmaceutical research and development today to deliver therapeutic innovations of tomorrow. Dive into our perspectives at: https://lnkd.in/e53m8qDY Pia Kürzdörfer, Ann (Andrea) Graf, Christoph Koenen, Tobias Ludwig, Astrid Scherer, Sarah Kuld, Belinda von Niederhaeusern, PhD, Dr. Julia Wagle, Michael Busse, Michael Heß, Dr. Marco Penske, Han Steutel

Tomorrow, we're teaming up with FINGERPOST for a panel discussion on the crucial role of market access in the biotech industry. This event is a must for startup biotechs, industry investors and personnel from large pharmaceutical companies, as it promises to broaden participants’ understanding of market access and its potential to shape drug development’s future. Attendees will learn the importance and timing of integrating market access considerations into their commercial planning. Save your spot: https://bit.ly/3zRUFWb

🌟 AUSTAR Pharma Conference 2024 Wrap-Up 🌟 Today, AUSTAR convened a thought-provoking seminar about automation and digitalization in the pharmaceutical field, and as we reflect on the day, it's clear our industry is ready for a new era of innovation and collaboration. The theme "Breaking Free, Rising Above" resonated strongly, gathering experts to discuss the pharmaceutical future. We connected with leaders and explored new paths together, addressing current challenges and mapping out a sustainable, prosperous future. It was a day of inspiring conversations, and we're thrilled about what's next. Let's continue to break through barriers and rise together in the pharmaceutical field. #AUSTARPharmaSummit #PharmaInnovation #FutureOfPharma

We are excited to co-host the EUROPE-CHINA Biotech Business Forum during Bio-Europe in Stockholm, alongside Chime Biologics, which brought together senior leaders from the pharmaceutical industry to explore cross-border collaboration opportunities, drive growth, and create new avenues for global partnerships. During the forum, Leo Xie, Senior Vice President of Duoning Biotech, shared insights with attending industry thought leaders about how Duoning—a one-stop bioprocessing solution platform—can better support biopharmaceutical companies and Contract Development and Manufacturing Organizations (CDMOs) in Europe. He discussed how the company integrates into the local culture and builds a robust supply chain to help partners accelerate their journey from development to commercialization in a cost-effective and flexible manner. For more information, check out the video here, or contact us at [email protected] for updates on future events! #Duoning #BioEurope #ChimeBiologics #Biotech #Bioprocessing #Biomanufacturing #CDMO